Breast Cancer : Targets and Therapy最新文献

{"title":"A Prospective Tumour Marker for Breast Cancer: YWHAB and Its Role in Promoting Oncogenic Phenotypes.","authors":"Vaishnavi L Gopaul, Lacey Winstone, Beatrice G Gatien, Braydon D Nault, Sujit Maiti, Reid M Opperman, Mousumi Majumder","doi":"10.2147/BCTT.S479384","DOIUrl":"https://doi.org/10.2147/BCTT.S479384","url":null,"abstract":"<p><strong>Background: </strong>YWHAB (14-3-3 Beta) was found in the secretome of miR-526b and miR-655 overexpressed breast cancer (BRCA) cell lines. The potential of YWHAB as a therapeutic target or biomarker for BRCA is investigated here.</p><p><strong>Methods: </strong>After YWHAB was knocked down with siRNA, BRCA cell lines were used for in vitro assays (proliferation, migration, epithelial-to-mesenchymal transition). In silico analysis and in situ validation with BRCA plasma and biopsy tissues were used to test YWHAB's biomarker potential.</p><p><strong>Results: </strong>YWHAB RNA and protein expression are elevated in aggressive BRCA cell lines, and the knockdown of YWHAB inhibited cell migration, proliferation, and EMT in all subtypes of tumour cell lines. YWHAB expression is significantly higher in BRCA biopsy tissue and blood plasma compared to control tissues and benign plasmas. YWHAB is expressed in all hormonal subtypes of BRCA tumours and has shown increased expression in advanced tumour stages. Its high expression is linked to poor patient survival. YWHAB is a sensitivity tumour marker (AUC of 0.7340, p = 0.0012) but is not a promising blood biomarker. Nevertheless, combined with pri-miR-526b, YWHAB mRNA expression shows potential as a BRCA blood biomarker (AUC of 0.711, p = 0.032), which must be validated in a larger sample set.</p><p><strong>Conclusion: </strong>We elucidate the novel role of YWHAB as a therapeutic target in BRCA, given that its inhibition mitigated aggressive phenotypes across all tumour subtypes, including triple-negative breast cancer. Furthermore, <i>YWHAB</i> emerges as a potential tumour marker, exhibiting high expression in metastatic BRCA and correlating with poor patient survival; however, it is not a sensitive blood biomarker.</p>","PeriodicalId":9106,"journal":{"name":"Breast Cancer : Targets and Therapy","volume":"16 ","pages":"935-956"},"PeriodicalIF":3.3,"publicationDate":"2024-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11656333/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142863394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Clinical Study of Intratumoral and Peritumoral Radiomics Based on DCE-MRI for HER-2 Positive and Low Expression Prediction in Breast Cancer.","authors":"Yiyan Shang, Yunxia Wang, Yaxin Guo, Shunian Li, Jun Liao, Menglu Hai, Meiyun Wang, Hongna Tan","doi":"10.2147/BCTT.S497770","DOIUrl":"https://doi.org/10.2147/BCTT.S497770","url":null,"abstract":"<p><strong>Background: </strong>Core biopsy sampling may not fully capture tumor heterogeneity. Radiomics provides a non-invasive method to assess tumor characteristics, including both the core and surrounding tissue, with the potential to improve the accuracy of HER-2 status prediction.</p><p><strong>Objective: </strong>To explore the clinical value of intratumoral and peritumoral radiomics features from dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) for preoperative prediction of human epidermal growth factor receptor-2 (HER-2) expression status in breast cancer.</p><p><strong>Methods: </strong>Two tasks were designed, including Task1-distinguished HER-2 positive and HER-2 negative from 382 breast cancer patients and Task2-distinguished HER-2 low and HER-2 zero expression from 249 patients with HER-2 negative. Three radiomics models (intratumoral, peritumoral 5 mm, intratumoral+peritumoral 5 mm) were constructed based on decision tree, and clinical combined radiomics models were constructed with logistic regression based on clinicopathological features and radscore. The area under the curve (AUC), sensitivity, specificity, accuracy and decision curve analysis (DCA) were used to evaluate the predictive performance of models.</p><p><strong>Results: </strong>Estrogen receptor (ER), progesterone receptor (PR) and Ki67 showed statistically significant in the different groups of HER-2 expression. Additionally, magnetic resonance imaging-reported axillary lymph nodes (MRI-reported ALN) in the positive and negative groups and histological grade in the low and zero expression groups showed significant differences (all <i>P</i> < 0.05). For task 1, the peritumoral radiomics model outperformed the other two radiomics models, with AUC values of 0.774 and 0.727 in the training and testing sets, respectively. For task 2, intratumoral + peritumoral radiomics model in the testing set showed the best predictive performance among the three radiomics models, and the AUC values were 0.777. The addition of clinicopathological features slightly altered the AUC values in both tasks.</p><p><strong>Conclusion: </strong>Both radiomics methods based on DCE-MRI and the nomogram are helpful for preoperative prediction of HER-2 expression status.</p>","PeriodicalId":9106,"journal":{"name":"Breast Cancer : Targets and Therapy","volume":"16 ","pages":"957-972"},"PeriodicalIF":3.3,"publicationDate":"2024-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11656331/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142863412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the Complexity of Pan-Cancer: Gene Convergences and in silico Analyses.","authors":"Leandro Teodoro, Ana Claudia O Carreira, Mari C Sogayar","doi":"10.2147/BCTT.S489246","DOIUrl":"https://doi.org/10.2147/BCTT.S489246","url":null,"abstract":"<p><p>Cancer is a complex and multifaceted group of diseases characterized by highly intricate mechanisms of tumorigenesis and tumor progression, which complicates diagnosis, prognosis, and treatment. In recent years, targeted therapies have gained prominence by focusing on specific mutations and molecular features unique to each tumor type, offering more effective and personalized treatment options. However, it is equally critical to explore the genetic commonalities across different types of cancer, which has led to the rise of pan-cancer studies. These approaches help identify shared therapeutic targets across various tumor types, enabling the development of broader and potentially more widely applicable treatment strategies. This review aims to provide a comprehensive overview of key concepts related to tumors, including tumorigenesis processes, the tumor microenvironment, and the role of extracellular vesicles in tumor biology. Additionally, we explore the molecular interactions and mechanisms driving tumor progression, with a particular focus on the pan-cancer perspective. To achieve this, we conducted an in silico analysis using publicly available datasets, which facilitated the identification of both common and divergent genetic and molecular patterns across different tumor types. By integrating these diverse areas, this review offers a clearer and deeper understanding of the factors influencing tumorigenesis and highlights potential therapeutic targets.</p>","PeriodicalId":9106,"journal":{"name":"Breast Cancer : Targets and Therapy","volume":"16 ","pages":"913-934"},"PeriodicalIF":3.3,"publicationDate":"2024-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11651076/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142845985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of Hematological Parameters and the Associated Factors Among Women with and without Breast Cancer: A Case-Control Study.","authors":"Abdul Baset Abbas, Shima Al-Gamei, AmatAlraheem Naser, Ahlam Al-Oqab, Khawla Alduhami, Manal Al-Sabri, Asmahan Al-Qasem, Mona Gharama, Amal Mohammed, Shuaib Ahmed, Malek Al-Glal","doi":"10.2147/BCTT.S497313","DOIUrl":"10.2147/BCTT.S497313","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer (BC) is the most popular and dangerous cancer, with a high mortality rate. Hematological parameters are often used in routine diagnosis of numerous disorders. Therefore, the study aimed to evaluate hematological parameters amongst women with and without BC.</p><p><strong>Methodology: </strong>Briefly, 200 blood samples (100 cases and 100 controls) were collected at Life Center of Breast Cancer Control, Ibb City, Yemen. The whole blood samples were tested immediately for complete blood count (CBC) parameters. Socio-demographic and reproductive characteristics were collected by using a standardized questionnaire. Kolmogorov-Smirnov test, Unpaired <i>t</i>-test, Mann-Whitney test, Fisher's exact test and chi-square test for trends were calculated using GraphPad Prism 8.0.1. <i>P</i>-values ≤0.05 were statistically significant.</p><p><strong>Results: </strong>The mean and standard deviation (SD) revealed significant differences between BC group and the healthy control group attributed to the variables of age (<i>P</i><0.0001), weight (<i>P</i><0.0001), residence (<i>P</i>=0.0218), employment state (<i>P</i><0.0001), economic state (<i>P</i>=0.0003), education levels (<i>P</i><0.0001), regular exercise (<i>P</i><0.0001) and a strict diet (<i>P</i><0.0008). Marital state, marital age, number of births, and use of contraceptives demonstrated statistical significance (<i>P</i><0.0001, <i>P</i>=0.0008, <i>P</i>=0.0009, and <i>P</i><0.0001, respectively). Additionally, Hb, RBCs, WBCs count, neutrophils, lymphocytes and monocytes displayed significant differences (<i>P</i>=0.0393, <i>P</i>=0.0045, <i>P</i>=0.0327, <i>P</i>=0.0441, <i>P</i>=0.0098 and <i>P</i><0.0001, respectively).</p><p><strong>Conclusion: </strong>Hb, RBCs, WBCs, neutrophils, lymphocytes, monocytes and other parameters scored high points of evidence for BC surveillance. Further studies are required to evaluate hematological parameter differences and biochemical parameters after or during chemotherapy or mastectomy.</p>","PeriodicalId":9106,"journal":{"name":"Breast Cancer : Targets and Therapy","volume":"16 ","pages":"877-885"},"PeriodicalIF":3.3,"publicationDate":"2024-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11645957/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142827450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Novel Peroxisome-Related Gene Signature Predicts Breast Cancer Prognosis and Correlates with T Cell Suppression.","authors":"Yunxiang Wang, Sheng Xu, Junfeng Liu, Pan Qi","doi":"10.2147/BCTT.S490154","DOIUrl":"10.2147/BCTT.S490154","url":null,"abstract":"<p><strong>Background: </strong>Peroxisomes are increasingly linked to cancer development, yet the prognostic role of peroxisome-related genes (PRGs) in breast cancer remains unclear.</p><p><strong>Objective: </strong>This study aimed to construct a prognostic model based on PRG expression in breast cancer to clarify their prognostic value and clinical implications.</p><p><strong>Methods: </strong>Transcriptomic data from TCGA and GEO were used for training and validation cohorts. TME characteristics were analyzed with ESTIMATE, MCP-counter, and CIBERSORT algorithms. qPCR validated mRNA expression levels of risk genes, and data analysis was conducted in R.</p><p><strong>Results: </strong>Univariate and multivariate Cox regression identified a 7-gene PRG risk signature (ACBD5, ACSL5, DAO, NOS2, PEX3, PEX10, and SLC27A2) predicting breast cancer prognosis in training (n=1069), internal validation (n=327), and external validation (merged from four GEO datasets, n=640) datasets. While basal and Her2 subtypes had higher risk scores than luminal subtypes, a significant prognostic impact of the PRG risk signature was seen only in luminal subtypes. The high-risk subgroup exhibited a higher frequency of focal synonymous copy number alterations (SCNAs), arm-level amplifications and deletions, and single nucleotide variations. These increased genomic aberrations were associated with greater immune suppression and reduced CD8+ T cell infiltration. Bulk RNA sequencing and single-cell analyses revealed distinct expression patterns of peroxisome-related genes (PRGs) in the breast cancer TME: PEX3 was primarily expressed in malignant and stromal cells, while ACSL5 showed high expression in T cells. Additionally, the PRG risk signature demonstrated efficacy comparable to that of well-known biomarkers for predicting immunotherapy responses. Drug sensitivity analysis revealed that the PRG high-risk subgroup was sensitive to inhibitors of BCL-2 family proteins (BCL-2, BCL-XL, and MCL1) and other kinases (PLK1, PLK1, BTK, CHDK1, and EGFR).</p><p><strong>Conclusion: </strong>The PRG risk signature serves as a promising biomarker for evaluating peroxisomal activity, prognosis, and responsiveness to immunotherapy in breast cancer.</p>","PeriodicalId":9106,"journal":{"name":"Breast Cancer : Targets and Therapy","volume":"16 ","pages":"887-911"},"PeriodicalIF":3.3,"publicationDate":"2024-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11639899/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142827449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psychological Stress and Its Correlations to Patients with Acute Lymphedema After Breast Cancer Surgery.","authors":"Li-Ping Ge, Lichen Tang, WenJia Zuo, Changmin Zhou, Tianhao Gao, Yun Li, Cuixia Fu, Jiajia Qiu, Ping Li, Rongrong Lu, Li Chen, Yunzi Xue, Zhou Shen, Zhimin Shao, Genhong Di, Wei Feng","doi":"10.2147/BCTT.S485827","DOIUrl":"10.2147/BCTT.S485827","url":null,"abstract":"<p><strong>Background: </strong>Lymphedema and psychological distress, including anxiety and depression, are common in breast cancer patients post-surgery. This study aimed to assess the incidence and determinants of anxiety and depression in patients with acute lymphedema (ALE) following breast cancer surgery.</p><p><strong>Methods: </strong>A retrospective study was conducted on 1613 breast cancer patients who underwent surgery at Fudan University Shanghai Cancer Center in 2018. ALE was defined as lymphatic fluid accumulation causing limb swelling and was classified by the difference in arm circumference. Anxiety and depression were evaluated using the Hospital Anxiety and Depression Scale (HADS) at discharge. Descriptive statistics and logistic regression were used to identify psychological distress-related factors.</p><p><strong>Results: </strong>Among the 1613 patients, 363 (22.5%) had ALE. Anxiety was observed in 31% and depression in 21% of patients. ALE significantly impacted anxiety in the multivariate analysis (OR = 1.57, 95% CI: [1.04-2.38], P = 0.033). Multivariate analysis of ALE patients showed that longer hospital stays (OR = 0.51, 95% CI: [0.30-0.88], P = 0.017) and invasive disease (OR = 0.39, 95% CI: [0.19-0.78], P = 0.008) were associated with reduced anxiety; while lymph-vessel invasive disease was associated with increased anxiety (OR = 5.97, 95% CI: [1.15-30.97], P = 0.034). ALE had no significant impact on depression in the multivariate analysis. However, menopause (OR = 0.72, 95% CI: [0.56-0.94], P = 0.014) and longer hospitalization (OR = 1.30, 95% CI: [1.00-1.68], P = 0.047) influenced depression in all patients. In the ALE group, lymph node surgery was the only significant factor for depression (OR = 8.67, 95% CI: [1.56-48.23], P = 0.014) in the multivariate analysis.</p><p><strong>Conclusion: </strong>Psychological stress, influenced by both surgical factors and emotional states, is associated with ALE development. Addressing both psychological and surgical factors is crucial for improving outcomes and quality of life in post-surgery breast cancer patients.</p>","PeriodicalId":9106,"journal":{"name":"Breast Cancer : Targets and Therapy","volume":"16 ","pages":"867-876"},"PeriodicalIF":3.3,"publicationDate":"2024-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11630805/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142805790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of Harmaline in Inhibiting c-Myc, Altering Molecular Typing, and Promoting Apoptosis in Triple-Negative Breast Cancer.","authors":"Haoyi Xu, Yan Ma, Huiling Li, Xinyu Song, Yuanjing Liu, Zuliyaer Mierzhakenmu, Kang Yan, Rui Xu, Ziqian Zhao, Hongyi Yuan, Chao Dong","doi":"10.2147/BCTT.S487070","DOIUrl":"10.2147/BCTT.S487070","url":null,"abstract":"<p><strong>Objective: </strong>Triple-negative breast cancer (TNBC) lacks effective targeted, endocrine therapeutic agents and the development of novel agents is costly and time-consuming. The objective of this study was to identify pharmaceuticals and natural products utilized in clinical practice that have the potential to inhibit the expression of Cellular-myelocytomatosis oncogene (c-Myc), based on a review of the current literature. The aim was to assess the effect of the specified drugs on c-Myc expression in TNBC cells, determine the most potent inhibitor, and evaluate its impact on TNBC cell proliferation, invasive migration, and apoptosis, as well as the expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER-2) at both the gene and protein levels. Explore its potential for treatment or adjuvant therapy for triple-negative breast cancer.</p><p><strong>Methods: </strong>Quantitative real-time polymerase chain reaction (qRT-PCR) and Western blot were used to quantify gene and protein expression levels. Flow cytometry was employed to measure cell proliferation and apoptosis, while the Transwell assay was utilized to assess cell invasion and migration.</p><p><strong>Results: </strong>Harmaline emerged as the strongest inhibitor, significantly decreasing the expression of c-Myc at both the gene and protein levels in TNBC cells. It also inhibited cell proliferation, invasion, and migration while promoting apoptosis in TNBC cells. Additionally, there was a varying increase in the expression of ER and PR genes and proteins. While the expression of the HER-2 gene was elevated, there was no significant change in HER-2 protein levels. Notably, the expression of the phosphorylated HER-2 protein increased.</p><p><strong>Conclusion: </strong>Harmaline was found to promote apoptosis and inhibit cell proliferation, invasion, and migration in TNBC cells by targeting the inhibition of c-Myc. It also induced the re-expression of the ER, PR, and HER-2 genes, as well as the ER and PR proteins.</p>","PeriodicalId":9106,"journal":{"name":"Breast Cancer : Targets and Therapy","volume":"16 ","pages":"855-866"},"PeriodicalIF":3.3,"publicationDate":"2024-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11626956/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142799327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dysregulation of Fatty Acid Metabolism in Breast Cancer and Its Targeted Therapy.","authors":"Yue Chang, Rui Du, Fan Xia, Xiuli Xu, Hongzhi Wang, Xueran Chen","doi":"10.2147/BCTT.S496322","DOIUrl":"10.2147/BCTT.S496322","url":null,"abstract":"<p><p>Breast cancer has become the number one cancer worldwide, there are challenges in its prevention, diagnosis and treatment, especially the pathogenesis of triple negative breast cancer has not been clear and the treatment dilemma of metastatic breast cancer. Metabolic reprogramming is currently considered to be one of the hallmarks of cancer, and metabolic alterations in breast cancer, including enhanced glycolysis, tricarboxylic acid cycle activity, glutamine catabolism, and fatty acid biosynthesis, are manifested differently in different breast cancer subtypes and have a complex relationship with tumor growth, metastasis, death, and drug resistance. At present, inhibitors of fatty acid synthesis and oxidation related enzymes have a certain effect in the treatment of breast cancer. In this paper, we review the studies on fatty acid metabolism in breast cancer to better understand the mechanism of fatty acid metabolism in breast cancer pathogenesis and hope to provide new ideas for targeting fatty acid metabolism in the treatment of breast cancer.</p>","PeriodicalId":9106,"journal":{"name":"Breast Cancer : Targets and Therapy","volume":"16 ","pages":"825-844"},"PeriodicalIF":3.3,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11614585/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142766254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Feasibility Study of Pyrrolitinib-Based Dual-Target Therapy for Neoadjuvant Treatment of HER2-Positive Breast Cancer Patients.","authors":"Feng Zhao, Hongzhen Zhang","doi":"10.2147/BCTT.S481236","DOIUrl":"10.2147/BCTT.S481236","url":null,"abstract":"<p><strong>Background: </strong>HER2-positive breast cancer is one of the high-risk subtypes of breast cancer for which dual-targeted therapy has become an important treatment option. However, for some patients, complete control of the disease is still not possible and additional treatment is required. Pyrrolitinib, an inhibitor of ALK and MET, has shown promising efficacy in breast cancer treatment. The aim of this study was to investigate the feasibility of adjuvant intensive therapy with pyrrolitinib in the treatment of HER2-positive breast cancer tumors.</p><p><strong>Materials and methods: </strong>Twenty-eight patients with HER2-positive breast cancer who were treated at the Breast Surgery Department of the Provincial Hospital of Weihai City, Shandong Province, China, between January 1, 2019, and January 1, 2023, were selected for this study. All of these patients received dual-targeted therapy with the addition of pyrrolitinib therapy adjuvant intensive therapy. We recorded data on the patients' basic information, pathological characteristics, treatment regimens, effects of treatment regimens, and adverse reactions, and statistically analyzed them.</p><p><strong>Results: </strong>Of the 28 patients with HER2-positive breast cancer, all of them were added to adjuvant intensive therapy with pyrrolitinib. After examination of the samples during treatment, the breast cancer mass had been significantly reduced with the assistance of pyrrolitinib. In addition, no serious adverse reactions were found.</p><p><strong>Conclusion: </strong>Adjuvant intensification of pyrrolitinib in the treatment of HER2-positive breast cancer tumors is feasible. The results of this study suggest that pyrrolitinib is a safe and effective therapeutic option that can significantly improve the outcome of HER2-positive breast cancer. More studies are needed to further validate this finding.</p>","PeriodicalId":9106,"journal":{"name":"Breast Cancer : Targets and Therapy","volume":"16 ","pages":"845-853"},"PeriodicalIF":3.3,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11614581/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142766257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Survival Analysis of Radiotherapy for Internal Mammary Lymph Nodes After Modified Radical Mastectomy for T_1-3N₃M₀ the Lateral Quadrant Breast Cancer.","authors":"Xiumei Han, Die Jiang, Chaomang Zhu, Duojie Li, Hongmei Yin","doi":"10.2147/BCTT.S487335","DOIUrl":"https://doi.org/10.2147/BCTT.S487335","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to investigate the efficacy and survival analysis of internal mammary lymph nodes (IMLNI) radiotherapy after modified radical mastectomy for T_1-3N₃M₀ The lateral quadrant breast cancer.</p><p><strong>Materials and methods: </strong>A total of 124 patients who underwent adjuvant radiotherapy after modified radical mastectomy for breast cancer in the First Affiliated Hospital of Bengbu Medical University were included. The patients were divided into the internal mammary lymph node (IMLN) irradiation group, and sixty-two patients received postoperative chest wall + upper and infraclavicular lymph nodes + IMLNI,sixty-two patients in the non-IMLN irradiation group received postoperative radiotherapy to the chest wall + upper and infraclavicular lymph nodes. The radiotherapy dose was 45-50GY, The disease-free survival rate (DFS), survival rate (OS), local recurrence rate (LRR), distant metastasis rate (DM), and adverse radiation reactions were analyzed.</p><p><strong>Results: </strong>Median follow-up was 56 months (range 12-96). The 5-year OS in the IMLNI group and the non-IMLNI group were 80.6% and 79.8% (P>0.05), DFS was 62.9% and 59.7% (P>0.05), LRR was 22.6 and 21.0% (P>0.05), and DM was 25.8% and 33.9% (P>0.05), respectively. Multifactorial showed that T stage, PR status, vascular cancer embolism, it was an independent prognostic factor affecting the 5-year OS of patients, and PR expression status (P=0.038) was an independent prognostic factor affecting the 5-year LRR.</p><p><strong>Conclusion: </strong>For breast cancer patients located in the outer quadrant and more than 9 axillary lymph node positives, increasing IMNI failed to improve the 5-year prognosis of the patients, and for patients with late N stage, PR receptor-negative, and vascularity cancer thrombosis positive, the 5-year OS of breast cancer postoperative patients could be reduced, and the PR receptor positivity could reduce the 5-year LRR of patients. There was no significant difference in 5-year late radiation adverse effects between the IMLNI and non-IMLNI groups.</p>","PeriodicalId":9106,"journal":{"name":"Breast Cancer : Targets and Therapy","volume":"16 ","pages":"811-823"},"PeriodicalIF":3.3,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11608050/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142766255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}